Bruce Taillon, formerly the director of healthcare business development at Roche's 454 Life Sciences division, is now the head of global technology business development at Enzo Life Science. While at 454, Taillon helped develop the company's next-generation sequencing platforms, including for its potential use in diagnostic assays. He also has experience leading R&D teams in the areas of genomics, proteomics, and drug development.
Pathogenica founder and CEO Yemi Adesokan has been named by MIT's Technology Review as one of its top innovators under the age of 35, for his work on developing sequencing-based diagnostic tests that can identify pathogens. His company is aiming to launch an FDA-approved test to diagnose HPV by 2012, and is also working on tests that can monitor drug resistance in HIV patients (CSN 8/17/2011). Previously, Adesokan was a research fellow in genetics at Harvard Medical School. He holds a PhD in chemistry from the University of California, Irvine.